openPR Logo
Press release

Global Rituximab Biosimilar Market 2027: Top Key Players Amgen Inc., Pfizer Inc., Sandoz International GmbH, Celltrion Healthcare Co.,Ltd., Mylan Inc., Reliance Life Sciences, Teva Pharmaceutical Industries Ltd., Intas Biopharmaceuticals Ltd., C.H. Boehri

03-12-2019 06:19 AM CET | Health & Medicine

Press release from: InsightAce Analytic Pvt. Ltd.

Global Rituximab Biosimilar Market

Global Rituximab Biosimilar Market

Rituximab is a chimeric anti-CD20 antibody that binds to the CD20 antigen present on the normal and malignant B cells surface. It is indicated for the treatment of blood cancer (CD20-positive) such as chronic lymphocytic leukemia and non-Hodgkin’s lymphoma as well as autoimmune disorder such as Rheumatoid arthritis. Rituximab is marketed under the trade name of MabThera in Europe and rest of World, except Japan by Roche. In the United States it marketed as Rituxan by Genentech in partnership with Biogen Idec. In Japan it is marketed by Chugai and Zenyaku Kogyo Co. Ltd. It is approved in the U.S. in 1997 and by European Medical Agency in June 1998. Rituximab is one of the top selling pharmaceutical product of Roche Holding AG. Therefor many biosimilar pharmaceutical companies are focusing on product development of rituximab biosimilar to compel the biosimilar product market share. Some of the market players leading the global rituximab biosimilar market include Amgen Inc., Pfizer Inc., Sandoz International GmbH, Celltrion Healthcare Co.,Ltd., Mylan Inc., Reliance Life Sciences, Teva Pharmaceutical Industries Ltd., Intas Biopharmaceuticals Ltd., C.H. Boehringer Sohn AG & Ko. KG, and BioXpress Therapeutics SA.

Request For Sample @ https://bit.ly/2SYX06k

The rituximab biosimilar market is expected to grow at higher pace during forecast period, since the rituximab is one of the best seller drug product that accounts for around 2.1 million prescriptions worldwide since the market launch. In addition, rituximab has lost its patent in the United States and Europe in 2016 and 2013 respectively. Presence of strong pipeline products such as ABP 789, MabTas, Reditux, and JHL 101, increasing incidence of chronic disease (such as cancer, arthritis, and diabetes) are the other factor that boos the demand for the rituximab biosimilar market. Furthermore, rising demand for biosimilar drugs and entry of new pharmaceutical market players have boosted the growth of the rituximab biosimilar market during the forecast period. However, stringent regulatory approval process for the rituximab biosimilar is major restraining factor that hampers the growth of the rituximab biosimilar market. In addition, IP strategies used by the product innovator companies to fight against the biosimilar competition, such as advancement in original formulation or screening for some new indications restrain the growth of the rituximab biosimilar market. For instance, Roche announced the development of new formulation for Rituxan as strategy to fight against biosimilar competition.

Based on application, the global rituximab biosimilar market is segmented in non-Hodgkin’s lymphoma, chronic lymhocytic leukemia, rheumatoid arthritis and others. Other indication includes off-label use such as thrombocytopenia, macroglobulinemia, immune thrombocytopenic purpura, Burkitt lymphoma, autoimmune hemolytic anemia, and multiple sclerosis. Non-Hodgkin’s lymphoma and chronic lymphocytic leukemia segment are expected to grow at rapid pace during the forecast period owing to increasing incidence and prevalence rate of chronic disease. Based on distribution channel the global rituximab biosimilar market is segmented as hospital pharmacy, online pharmacy, retail pharmacy and others. Hospital pharmacy segment is expected to grow during forecast period due to increase in number of hospital visit and hospital stays for the treatment of different chronic disease.

At geographic level segmentation, the global rituximab biosimilar market has been categorized into Europe, Asia Pacific, North America, Latin America and Middle East & Africa. In terms of revenue, Europe is major contributor for the global rituximab biosimilar market. Europe is the major contributor to the global market owing to the loss of a rituximab patent in 2013. In June 2017, Sandoz announce the launch of first rituximab biosimilar in Europe.

Request For Table Of Content (TOC) @ https://bit.ly/2SYX06k

Europe is followed by North America which is second major revenue generator during the forecast period. The growth of the rituximab biosimilar market in North America is owing to factors such as strong clinical trial/product pipeline, increasing research and drug development activities propels rituximab biosimilar market growth in the region. Asia Pacific is third promising revenue contributor which is expected to grow at rapid pace in upcoming year. Countries such as Japan, India and China are major contributors for this market. Emerging and huge population base countries such as China and India offers tremendous market opportunities.

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products.

Contact Us:
Mr. John Smith
InsightAce Analytic Pvt. Ltd.
Pune, Maharashtra, India
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: https://www.insightaceanalytic.com
Follow Us on LinkedIn @ https://bit.ly/2tBXsgS
Follow Us On Facebook @ https://bit.ly/2H9jnDZ

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Rituximab Biosimilar Market 2027: Top Key Players Amgen Inc., Pfizer Inc., Sandoz International GmbH, Celltrion Healthcare Co.,Ltd., Mylan Inc., Reliance Life Sciences, Teva Pharmaceutical Industries Ltd., Intas Biopharmaceuticals Ltd., C.H. Boehri here

News-ID: 1647143 • Views: 428

More Releases from InsightAce Analytic Pvt. Ltd.

Global Continuous Glucose Monitoring (CGM) Sensors Market 2021 | Medtronics, Dex …
InsightAce Analytic Pvt. Ltd. features the release of the market research report on “Global Continuous Glucose Monitoring (CGM) Sensors Market Assessment – Industry Analysis, Competitive Analysis, COVID 19 Impact Analysis, and Revenue & Volume Forecast Till 2028” According to the latest research by InsightAce Analytic, the global continuous glucose monitoring (CGM) sensors market was valued at US$ 2,786.4 Mn in 2019 and it is expected to reach US$ 11,747.4 million
Global Agricultural Microbials Market 2021 | BASF SE , Bayer CropScience, Sumito …
InsightAce Analytic Pvt. Ltd. features the release of the market research report on “Global Agricultural Microbials Market Assessment – – Industry Analysis, Competitive Analysis, COVID 19 Impact Analysis, and Revenue Forecast Till 2030” According to the latest research by InsightAce Analytic, the global market was valued at US$ XX Mn in 2020 and it is expected to reach US$ XX million in 2030, recording a promising CAGR of XX% from
Global Longevity and Anti-Senescence Therapy Market 2021 | Acorda Therapeutics, …
InsightAce Analytic Pvt. Ltd. features the release of market research report on “Global Longevity and Anti-Senescence Therapy Market Assessment – Industry Analysis, Competitive Analysis, COVID 19 Impact Analysis, and Revenue Forecast Till 2028” According to the latest research by InsightAce Analytic, the global market expected to record a promising CAGR during the period of 2020-2028. Longevity and Anti-Senescence therapies are targeted at providing therapeutic options to combat the aging-related functional declines
Global Vaccine Cold Chain Logistics Market 2021 | Cryoport, DHL Express, GAC, Ly …
InsightAce Analytic Pvt. Ltd. announces the release of the market research report on “Global Vaccine Cold Chain Logistics Market Assessment – Industry Analysis, Competitive Analysis, COVID 19 Impact Analysis, and Revenue Forecast To2028” According to the latest research by InsightAce Analytic, the global market was valued at US$ XX Mn in 2020 and it is expected to reach US$ XX million in 2028, at a CAGR of XX% during the

All 5 Releases


More Releases for Europe

Synthetic Biology Market – Europe
Synthetic Biology Market Europe is expected to reach USD XX Billion by 2026 from USD XX Billion in 2016 at a CAGR of XX% (Detailed analysis of the market CAGR is provided in the report). Synthetic biology has expanded into various interdisciplinary fields that may be defined as the combination of artificial design and engineering to produce biological systems, chemicals or living organisms. Synthetic biology is also used for improving applications
Europe Wooden Doors Market
Europe Wooden Doors Market https://www.qandqmarketresearch.com/reports/wooden-doors-market-78 This report studies the Wooden Doorsmarket status and outlook of Europe and major countries, from angles of players, countries, product types and end industries; this report analyzes the top players in Europe and major countries, and splits the Wooden Doors market by product type and applications/end industries. The global Wooden Doors market is valued at XX million USD in 2018 and is expected to reach XX million
Europe Radiotherapy Market
The Europe Radiotherapy Market research report consists of a primary and secondary research along with an in-depth analysis of the quantitative and qualitative aspects by the expert industry analysts and professionals, leading management bodies, to gain a profound insight of the industry as well as the industry performance. The Europe Radiotherapy Market report presents a lucid picture of the current industry landscape, including the historical and projected market size, based
Europe Business Assembly
The Europe Business Assembly (EBA) is an international corporation for the evolution and implementation of economic and social development. The company was established in April 2000 and its history shows a plethora of promising initiatives, creative growth and professional victories. EBA’s activity demonstrates the capabilities and power of professional partnership. The year 2000 saw the beginning and the foundation of EBA with the signing of the memorandum of cooperation and
Smartsourcing in Eastern Europe
In 2008 the outsourcing business of Eastern Europe was estimated at nearly $2 billion, representing just a tiny fraction of the global IT outsourcing market, estimated at about $386 billion. According to the Gartner Dataquest predictions, in the next four years Eastern Europe is expected to outstrip the rest of the offshore market concentrated mainly in the “classical” locations like India. By 2010 Eastern Europe’s IT outsourcing market share is
Home Control conquers Europe
European Home Control Summit attracts participation from leading International companies and organizations 29. February 2008 - Copenhagen/Frankfurt - The first European Wireless Home Control Summit on 9 April 2008, taking place parallel to Light + Building, features leading companies such as Merten, Horstmann, Danfoss, and market researcher Parks Associates as well as publicly funded organizations like the Danish Energy Saving Trust (DEST) presenting the newest trends, products and market strategies pertaining